| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

8 April 2024

ORYZON announces U.S. FDA clearance of CTEP-CRADA Phase I/II clinical trial sponsored by NCI for iadademstat plus immune checkpoint inhibitors in 1L extensive stage Small Cell Lung Cancer

29-30 April 2024

LSX World Congress

London

United Kingdom

22-23 April 2024

Swiss Biotech Day 2024

Markthalle

Basel

Switzerland

16-17 April 2024

Van Lanschot Kempen Life Sciences Conference

Amsterdam

Netherlands

10 April 2024

Investing in Oncology Forum 2024

IVA Konferenscenter

Stockholm

Sweden

5 April 2024

ORYZON to provide corporate progress updates at several events in April

4 April 2024

ORYZON receives the INNOVATIVE SME seal from the Spanish Ministry of Science and Innovation

26 February 2024

ORYZON reports financial results and corporate update for quarter ended December 31, 2023

18-20 March 2024

BIO-Europe Spring 2024

CCIB

Barcelona

Spain

28-29 February 2024

17th Annual European Life Sciences CEO Forum

Hilton Zurich Airport Hotel

Zurich

Switzerland

Pagination

First page «
Previous page ‹
Page 4
Page 5
Page 6
Page 7
Current page 8
Page 9
Page 10
Page 11
Page 12
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel